Chemours Plummets 32% as Alta Advisers Bets $13M

To the uninitiated, the numbers might seem a ledger of losses: $12.02 per share where once there were higher peaks; a net income of ($320 million) over trailing twelve months; a S&P 500 that strides forward while Chemours lags, a limping figure in the grand procession. Yet within these figures lies a paradox-the very essence of markets where value is not merely measured, but imagined. Alta Fundamental Advisers, in acquiring 800,000 shares representing 5.41% of their U.S. equity assets, has cast its lot with a company whose fate now hangs in the balance between cyclical misfortune and structural decay.






